Neuropharma

Impel Pharmaceuticals (formerly Impel NeuroPharma) is a commercial-stage biopharmaceutical company focused on developing transformative therapies for central nervous system (CNS) disorders. The company's core technology is the Precision Olfactory Delivery (POD) platform, a proprietary drug-device combination designed to deliver therapeutics to the vascular-rich upper nasal space for rapid and consistent absorption. Its lead product, Trudhesa (dihydroergotamine mesylate), was FDA-approved in 2021 for the acute treatment of migraine in adults. The company's pipeline also included candidates for Parkinson's disease and acute agitation, though the company filed for Chapter 11 bankruptcy in late 2023 and subsequently sold its assets to Viatris.